Author(s):
Mykola Rybalkin, Tatiana Diadiun, Natalia Khokhlenkova, Yuliia Azarenko, Serhiy Stepanenko
Email(s):
diadiunscience@gmail.com
DOI:
10.52711/0974-360X.2021.00565
Address:
Mykola Rybalkin1, Tatiana Diadiun2*, Natalia Khokhlenkova1, Yuliia Azarenko1, Serhiy Stepanenko3
1Biotechnology Department, National University of Pharmacy, Kharkiv.
2Commodity Science Department, National University of Pharmacy, Kharkiv.
3Technologies of Pharmaceutical Preparations Department, National University of Pharmacy, Kharkiv.
*Corresponding Author
Published In:
Volume - 14,
Issue - 6,
Year - 2021
ABSTRACT:
The objective of this work was to determine the C. albicans fungus protein concentration at intramuscular introduction in therapy of candidiasis. Therapeutic effect of C. albicans fungus proteins in concentrations 1, 2, 3, 4 and 5mg/mL has been examined in white mice. Animals were infected intraperitoneally with suspension of C. albicans fungus strain CCM 335-867 in the amount of 20 million cells per 1mL volume. After 5 days and repeatedly after 14 days mice were injected intramuscularly in the upper back hind paw with proteins of Candida fungus cells of volume 0.2mL. 14 days after each injection, the determination of the protective functions of the animal body has been carried out by the titer of specific C. albicans antibodies during immunoassay. According to the data obtained during studies on the treatment of candidiasis, it has been found that in the intramuscular route of administration after the first injection with C. albicans protein concentration of 3 mg/mL antibody titers increased 2 times, and after the second - 8 times. Proteins of C. albicans fungus at a concentration of 3 mg/mL activate the body's defence mechanisms.
Cite this article:
Mykola Rybalkin, Tatiana Diadiun, Natalia Khokhlenkova, Yuliia Azarenko, Serhiy Stepanenko. Determination of Candida albicans fungus proteins concentration by Elisa method at Intramuscular Introduction in Candidiasis Therapy. Research Journal of Pharmacy and Technology. 2021; 14(6):3249-2. doi: 10.52711/0974-360X.2021.00565
Cite(Electronic):
Mykola Rybalkin, Tatiana Diadiun, Natalia Khokhlenkova, Yuliia Azarenko, Serhiy Stepanenko. Determination of Candida albicans fungus proteins concentration by Elisa method at Intramuscular Introduction in Candidiasis Therapy. Research Journal of Pharmacy and Technology. 2021; 14(6):3249-2. doi: 10.52711/0974-360X.2021.00565 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-6-55
REFERENCES:
1. Lisovskaya AM, Aleshukina AV. The study of the biological properties of Candida spp. Isolated from different loci in outpatients. Problems of medical mycology. - 2006. - Vol. 8, No.2. - P. 57.
2. Pappas P. G. Invasive candidiasis. Infect. Dis. Clin North Am. - 2006. – No. 20. –P. 485–506.
3. Saigal S, Bhargava A, Mehra SK, Dakwala F. Identification of Candida albicans by using different culture medias and its association in potentially malignant and malignant lesions. Contemp Clin Dent. 2011;2(3):188-193. doi: 10.4103/0976-237X.86454
4. Kabir MA, Ahmad Z. Candida infections and their prevention. ISRN Prev Med. 2012;2013:763628. Published 2012 Nov 4. doi:10.5402/2013/763628
5. Diekema D., Arbefeville S., Boyken L., Kroeger J.& Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades Diagn. Microbiol. Infect. Dis. - 2012. 73. P. 45–48.
6. Borshch SK, Masliak TR. Combined use of antifungal agents and probiotics in combustiology for the treatment and prevention of candidiasis and irritable bowel syndrome. Modern Gastroenterology. - 2011. – No. 4. - P. 30–39.
7. LeibundGut-Landmann S, Wüthrich M, Hohl TM. Immunity to fungi. Curr Opin Immunol. 2012;24(4):449-458. doi:10.1016/j.coi.2012.04.007
8. Aditi Grover, BS Bhandari, Nishant Rai, Pramesh C Lakhera. Candida albicans vaccines Biotechnology International. - 2010.-Vol. 3, 1. P. 4-17.
9. Xin H, Dziadek S, Bundle DR, Cutler JE. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A. 2008;105(36):13526-13531. doi:10.1073/pnas.0803195105
10. Cassone A. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol. 2013;11(12):884-891. doi:10.1038/nrmicro3156
11. Edwards JE. Fungal cell wall vaccines: an update. J Med Microbiol. 2012;61(Pt 7):895-903. doi:10.1099/jmm.0.041665-0
12. Han Y, Rhew KY. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis. Arch Pharm Res. 2012;35(11):2021-2027. doi:10.1007/s12272-012-1120-9
13. Zhukova NV, Krivosheeva IM. Modern vaccines: characterization and classification Crimean Therapeutic Journal. - 2013. - № 2. - P. 99–104.
14. Rybalkin MV Determination of the optimal method of disintegration of Candida albicans and Candida tropicalis fungal cells. Topical issues in pharmaceutical and medical science and practice. 2014. № 2 (15). Pp. 71–75.
15. Rybalkin MV, Strelnikov LS Scientific and experimental substantiation of Candida antigen purification technology. Scientific Journal «ScienceRise: Pharmaceutical Science». 2017. № 1 (5). Pp. 62–65.